nodes	percent_of_prediction	percent_of_DWPC	metapath
Tiagabine—SLC6A1—NRF2 pathway—DNAJB1—liver cancer	0.0129	0.0513	CbGpPWpGaD
Tiagabine—SLC6A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A2—liver cancer	0.012	0.048	CbGpPWpGaD
Tiagabine—SLC6A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC40A1—liver cancer	0.0115	0.0458	CbGpPWpGaD
Tiagabine—CYP3A4—Felbamate Metabolism—CYP2E1—liver cancer	0.0106	0.0422	CbGpPWpGaD
Tiagabine—SLC6A1—Monoamine Transport—MAPK14—liver cancer	0.00836	0.0333	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—GSTA3—liver cancer	0.00738	0.0294	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—GSTA4—liver cancer	0.00675	0.0269	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—GSTA2—liver cancer	0.00658	0.0262	CbGpPWpGaD
Tiagabine—CYP3A4—Liver X Receptor Pathway—SCD—liver cancer	0.00636	0.0254	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—GSTA1—liver cancer	0.00635	0.0253	CbGpPWpGaD
Tiagabine—SLC6A1—Transmission across Chemical Synapses—GLUL—liver cancer	0.00605	0.0241	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—NFE2L2—liver cancer	0.00559	0.0223	CbGpPWpGaD
Tiagabine—SLC6A1—SLC-mediated transmembrane transport—SLC11A2—liver cancer	0.00547	0.0218	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—MYO5B—liver cancer	0.00543	0.0217	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.00543	0.0217	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—TGFA—liver cancer	0.00534	0.0213	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—GPX3—liver cancer	0.00534	0.0213	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—SERPINA1—liver cancer	0.00526	0.021	CbGpPWpGaD
Tiagabine—SLC6A1—SLC-mediated transmembrane transport—SLC40A1—liver cancer	0.00522	0.0208	CbGpPWpGaD
Tiagabine—SLC6A1—Neuronal System—GLUL—liver cancer	0.00464	0.0185	CbGpPWpGaD
Tiagabine—SLC6A1—Monoamine Transport—TNF—liver cancer	0.00397	0.0159	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—GGT1—liver cancer	0.00375	0.015	CbGpPWpGaD
Tiagabine—CYP3A4—Drug Induction of Bile Acid Pathway—NR1H4—liver cancer	0.00351	0.014	CbGpPWpGaD
Tiagabine—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I3—liver cancer	0.00345	0.0138	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—GSTP1—liver cancer	0.00337	0.0135	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—HMOX1—liver cancer	0.00333	0.0133	CbGpPWpGaD
Tiagabine—CYP3A4—Farnesoid X Receptor  Pathway—NR1H4—liver cancer	0.00321	0.0128	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—GSTM1—liver cancer	0.0031	0.0124	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—HGF—liver cancer	0.0031	0.0124	CbGpPWpGaD
Tiagabine—CYP3A4—Aflatoxin B1 metabolism—GSTM1—liver cancer	0.00294	0.0117	CbGpPWpGaD
Tiagabine—CYP3A4—Estrogen metabolism—GSTA1—liver cancer	0.00283	0.0113	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.00278	0.0111	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.00265	0.0106	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—ATP7B—liver cancer	0.00254	0.0101	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—ANXA2—liver cancer	0.00254	0.0101	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—NR1H4—liver cancer	0.0024	0.00959	CbGpPWpGaD
Tiagabine—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—liver cancer	0.00228	0.00911	CbGpPWpGaD
Tiagabine—CYP3A4—Constitutive Androstane Receptor Pathway—NR1I3—liver cancer	0.00208	0.00829	CbGpPWpGaD
Tiagabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1H4—liver cancer	0.00201	0.00804	CbGpPWpGaD
Tiagabine—CYP3A4—Fatty Acid Omega Oxidation—CYP2E1—liver cancer	0.00201	0.008	CbGpPWpGaD
Tiagabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—liver cancer	0.00198	0.0079	CbGpPWpGaD
Tiagabine—CYP3A4—Constitutive Androstane Receptor Pathway—GSTA2—liver cancer	0.00185	0.00739	CbGpPWpGaD
Tiagabine—SLC6A1—Transmission across Chemical Synapses—BRAF—liver cancer	0.00168	0.00671	CbGpPWpGaD
Tiagabine—CYP3A4—Xenobiotics—CYP2E1—liver cancer	0.00168	0.00669	CbGpPWpGaD
Tiagabine—CYP3A4—Tamoxifen metabolism—CYP2E1—liver cancer	0.00161	0.00644	CbGpPWpGaD
Tiagabine—CYP3A4—Aflatoxin activation and detoxification—GGT1—liver cancer	0.0016	0.0064	CbGpPWpGaD
Tiagabine—Decreased appetite—Sorafenib—liver cancer	0.00152	0.00203	CcSEcCtD
Tiagabine—Thrombophlebitis—Epirubicin—liver cancer	0.00152	0.00203	CcSEcCtD
Tiagabine—Ecchymosis—Doxorubicin—liver cancer	0.00152	0.00202	CcSEcCtD
Tiagabine—Mouth ulceration—Doxorubicin—liver cancer	0.00152	0.00202	CcSEcCtD
Tiagabine—Neoplasm—Doxorubicin—liver cancer	0.00152	0.00202	CcSEcCtD
Tiagabine—Bladder pain—Doxorubicin—liver cancer	0.00152	0.00202	CcSEcCtD
Tiagabine—Fatigue—Sorafenib—liver cancer	0.00151	0.00201	CcSEcCtD
Tiagabine—Constipation—Sorafenib—liver cancer	0.0015	0.002	CcSEcCtD
Tiagabine—Pain—Sorafenib—liver cancer	0.0015	0.002	CcSEcCtD
Tiagabine—Hypertonia—Doxorubicin—liver cancer	0.00147	0.00196	CcSEcCtD
Tiagabine—Eczema—Epirubicin—liver cancer	0.00146	0.00195	CcSEcCtD
Tiagabine—Abnormal vision—Doxorubicin—liver cancer	0.00146	0.00195	CcSEcCtD
Tiagabine—Eye pain—Epirubicin—liver cancer	0.00146	0.00195	CcSEcCtD
Tiagabine—Sepsis—Doxorubicin—liver cancer	0.00146	0.00194	CcSEcCtD
Tiagabine—Mental disability—Doxorubicin—liver cancer	0.00146	0.00194	CcSEcCtD
Tiagabine—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—liver cancer	0.00144	0.00575	CbGpPWpGaD
Tiagabine—Gastrointestinal pain—Sorafenib—liver cancer	0.00143	0.00191	CcSEcCtD
Tiagabine—Lymphadenopathy—Doxorubicin—liver cancer	0.00143	0.00191	CcSEcCtD
Tiagabine—Phlebitis—Doxorubicin—liver cancer	0.00141	0.00189	CcSEcCtD
Tiagabine—Thrombophlebitis—Doxorubicin—liver cancer	0.00141	0.00188	CcSEcCtD
Tiagabine—SLC6A1—Transmission across Chemical Synapses—RAF1—liver cancer	0.0014	0.0056	CbGpPWpGaD
Tiagabine—Increased appetite—Epirubicin—liver cancer	0.0014	0.00187	CcSEcCtD
Tiagabine—Dermatitis exfoliative—Epirubicin—liver cancer	0.0014	0.00186	CcSEcCtD
Tiagabine—Urticaria—Sorafenib—liver cancer	0.00139	0.00186	CcSEcCtD
Tiagabine—Abdominal pain—Sorafenib—liver cancer	0.00138	0.00185	CcSEcCtD
Tiagabine—Body temperature increased—Sorafenib—liver cancer	0.00138	0.00185	CcSEcCtD
Tiagabine—CYP3A4—Estrogen metabolism—GSTM1—liver cancer	0.00138	0.00552	CbGpPWpGaD
Tiagabine—Dermatitis bullous—Epirubicin—liver cancer	0.00138	0.00184	CcSEcCtD
Tiagabine—Eczema—Doxorubicin—liver cancer	0.00136	0.00181	CcSEcCtD
Tiagabine—Eye pain—Doxorubicin—liver cancer	0.00135	0.0018	CcSEcCtD
Tiagabine—Hypoglycaemia—Epirubicin—liver cancer	0.00135	0.0018	CcSEcCtD
Tiagabine—Hyponatraemia—Epirubicin—liver cancer	0.00132	0.00176	CcSEcCtD
Tiagabine—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.00132	0.00176	CcSEcCtD
Tiagabine—Diplopia—Epirubicin—liver cancer	0.00132	0.00176	CcSEcCtD
Tiagabine—Osteoarthritis—Epirubicin—liver cancer	0.00132	0.00176	CcSEcCtD
Tiagabine—CYP3A4—Estrogen metabolism—CYP1A1—liver cancer	0.00131	0.00523	CbGpPWpGaD
Tiagabine—Increased appetite—Doxorubicin—liver cancer	0.0013	0.00173	CcSEcCtD
Tiagabine—Affect lability—Epirubicin—liver cancer	0.0013	0.00173	CcSEcCtD
Tiagabine—Migraine—Epirubicin—liver cancer	0.0013	0.00173	CcSEcCtD
Tiagabine—Dermatitis exfoliative—Doxorubicin—liver cancer	0.00129	0.00172	CcSEcCtD
Tiagabine—Hypersensitivity—Sorafenib—liver cancer	0.00129	0.00172	CcSEcCtD
Tiagabine—SLC6A1—Neuronal System—BRAF—liver cancer	0.00129	0.00514	CbGpPWpGaD
Tiagabine—CYP3A4—Cytochrome P450 - arranged by substrate type—NR1H4—liver cancer	0.00128	0.0051	CbGpPWpGaD
Tiagabine—Dermatitis bullous—Doxorubicin—liver cancer	0.00127	0.0017	CcSEcCtD
Tiagabine—Face oedema—Epirubicin—liver cancer	0.00127	0.0017	CcSEcCtD
Tiagabine—SLC6A1—NRF2 pathway—TGFB1—liver cancer	0.00126	0.00504	CbGpPWpGaD
Tiagabine—SLC6A1—SLC-mediated transmembrane transport—ALB—liver cancer	0.00126	0.00502	CbGpPWpGaD
Tiagabine—Asthenia—Sorafenib—liver cancer	0.00126	0.00168	CcSEcCtD
Tiagabine—CYP3A4—Irinotecan Pathway—APC—liver cancer	0.00126	0.00501	CbGpPWpGaD
Tiagabine—Hypoglycaemia—Doxorubicin—liver cancer	0.00125	0.00167	CcSEcCtD
Tiagabine—Mood swings—Epirubicin—liver cancer	0.00125	0.00166	CcSEcCtD
Tiagabine—Pruritus—Sorafenib—liver cancer	0.00124	0.00165	CcSEcCtD
Tiagabine—Ataxia—Epirubicin—liver cancer	0.00124	0.00165	CcSEcCtD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—CYCS—liver cancer	0.00123	0.00489	CbGpPWpGaD
Tiagabine—Dehydration—Epirubicin—liver cancer	0.00122	0.00163	CcSEcCtD
Tiagabine—Hyponatraemia—Doxorubicin—liver cancer	0.00122	0.00163	CcSEcCtD
Tiagabine—Diplopia—Doxorubicin—liver cancer	0.00122	0.00163	CcSEcCtD
Tiagabine—Osteoarthritis—Doxorubicin—liver cancer	0.00122	0.00163	CcSEcCtD
Tiagabine—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.00122	0.00163	CcSEcCtD
Tiagabine—Liver function test abnormal—Epirubicin—liver cancer	0.00122	0.00162	CcSEcCtD
Tiagabine—Dry skin—Epirubicin—liver cancer	0.00121	0.00161	CcSEcCtD
Tiagabine—CYP3A4—Xenobiotics—CYP1A1—liver cancer	0.00121	0.00481	CbGpPWpGaD
Tiagabine—Orthostatic hypotension—Epirubicin—liver cancer	0.0012	0.0016	CcSEcCtD
Tiagabine—Migraine—Doxorubicin—liver cancer	0.0012	0.0016	CcSEcCtD
Tiagabine—Affect lability—Doxorubicin—liver cancer	0.0012	0.0016	CcSEcCtD
Tiagabine—Hypokalaemia—Epirubicin—liver cancer	0.0012	0.0016	CcSEcCtD
Tiagabine—Diarrhoea—Sorafenib—liver cancer	0.0012	0.0016	CcSEcCtD
Tiagabine—Face oedema—Doxorubicin—liver cancer	0.00118	0.00157	CcSEcCtD
Tiagabine—Gastritis—Epirubicin—liver cancer	0.00117	0.00155	CcSEcCtD
Tiagabine—Muscular weakness—Epirubicin—liver cancer	0.00116	0.00155	CcSEcCtD
Tiagabine—CYP3A4—Tamoxifen metabolism—CYP1A1—liver cancer	0.00116	0.00462	CbGpPWpGaD
Tiagabine—Dizziness—Sorafenib—liver cancer	0.00116	0.00154	CcSEcCtD
Tiagabine—Mood swings—Doxorubicin—liver cancer	0.00115	0.00154	CcSEcCtD
Tiagabine—Ataxia—Doxorubicin—liver cancer	0.00115	0.00153	CcSEcCtD
Tiagabine—Dysphagia—Epirubicin—liver cancer	0.00114	0.00152	CcSEcCtD
Tiagabine—Asthma—Epirubicin—liver cancer	0.00114	0.00152	CcSEcCtD
Tiagabine—Influenza—Epirubicin—liver cancer	0.00114	0.00152	CcSEcCtD
Tiagabine—Dehydration—Doxorubicin—liver cancer	0.00113	0.00151	CcSEcCtD
Tiagabine—Liver function test abnormal—Doxorubicin—liver cancer	0.00112	0.0015	CcSEcCtD
Tiagabine—Dry skin—Doxorubicin—liver cancer	0.00112	0.00149	CcSEcCtD
Tiagabine—Vomiting—Sorafenib—liver cancer	0.00111	0.00149	CcSEcCtD
Tiagabine—Orthostatic hypotension—Doxorubicin—liver cancer	0.00111	0.00148	CcSEcCtD
Tiagabine—Hypokalaemia—Doxorubicin—liver cancer	0.00111	0.00148	CcSEcCtD
Tiagabine—Angina pectoris—Epirubicin—liver cancer	0.00111	0.00148	CcSEcCtD
Tiagabine—Rash—Sorafenib—liver cancer	0.0011	0.00147	CcSEcCtD
Tiagabine—Dermatitis—Sorafenib—liver cancer	0.0011	0.00147	CcSEcCtD
Tiagabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	0.0011	0.00438	CbGpPWpGaD
Tiagabine—Headache—Sorafenib—liver cancer	0.0011	0.00146	CcSEcCtD
Tiagabine—Bronchitis—Epirubicin—liver cancer	0.00109	0.00146	CcSEcCtD
Tiagabine—Gastritis—Doxorubicin—liver cancer	0.00108	0.00144	CcSEcCtD
Tiagabine—SLC6A1—Neuronal System—RAF1—liver cancer	0.00108	0.00429	CbGpPWpGaD
Tiagabine—Muscular weakness—Doxorubicin—liver cancer	0.00107	0.00143	CcSEcCtD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—HMOX1—liver cancer	0.00107	0.00425	CbGpPWpGaD
Tiagabine—Dysuria—Epirubicin—liver cancer	0.00106	0.00142	CcSEcCtD
Tiagabine—Influenza—Doxorubicin—liver cancer	0.00105	0.0014	CcSEcCtD
Tiagabine—Asthma—Doxorubicin—liver cancer	0.00105	0.0014	CcSEcCtD
Tiagabine—Dysphagia—Doxorubicin—liver cancer	0.00105	0.0014	CcSEcCtD
Tiagabine—Pollakiuria—Epirubicin—liver cancer	0.00105	0.0014	CcSEcCtD
Tiagabine—Nausea—Sorafenib—liver cancer	0.00104	0.00139	CcSEcCtD
Tiagabine—Photosensitivity reaction—Epirubicin—liver cancer	0.00104	0.00139	CcSEcCtD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.00104	0.00414	CbGpPWpGaD
Tiagabine—Weight increased—Epirubicin—liver cancer	0.00104	0.00138	CcSEcCtD
Tiagabine—Weight decreased—Epirubicin—liver cancer	0.00103	0.00137	CcSEcCtD
Tiagabine—Hyperglycaemia—Epirubicin—liver cancer	0.00103	0.00137	CcSEcCtD
Tiagabine—Angina pectoris—Doxorubicin—liver cancer	0.00103	0.00137	CcSEcCtD
Tiagabine—Pneumonia—Epirubicin—liver cancer	0.00102	0.00136	CcSEcCtD
Tiagabine—Bronchitis—Doxorubicin—liver cancer	0.00101	0.00135	CcSEcCtD
Tiagabine—Renal failure—Epirubicin—liver cancer	0.000997	0.00133	CcSEcCtD
Tiagabine—Neuropathy peripheral—Epirubicin—liver cancer	0.000994	0.00133	CcSEcCtD
Tiagabine—Stomatitis—Epirubicin—liver cancer	0.000989	0.00132	CcSEcCtD
Tiagabine—Urinary tract infection—Epirubicin—liver cancer	0.000986	0.00132	CcSEcCtD
Tiagabine—Conjunctivitis—Epirubicin—liver cancer	0.000986	0.00132	CcSEcCtD
Tiagabine—Dysuria—Doxorubicin—liver cancer	0.000984	0.00131	CcSEcCtD
Tiagabine—Sweating—Epirubicin—liver cancer	0.000973	0.0013	CcSEcCtD
Tiagabine—Pollakiuria—Doxorubicin—liver cancer	0.000973	0.0013	CcSEcCtD
Tiagabine—Haematuria—Epirubicin—liver cancer	0.000967	0.00129	CcSEcCtD
Tiagabine—Photosensitivity reaction—Doxorubicin—liver cancer	0.000961	0.00128	CcSEcCtD
Tiagabine—Weight increased—Doxorubicin—liver cancer	0.000958	0.00128	CcSEcCtD
Tiagabine—Epistaxis—Epirubicin—liver cancer	0.000957	0.00128	CcSEcCtD
Tiagabine—Weight decreased—Doxorubicin—liver cancer	0.000952	0.00127	CcSEcCtD
Tiagabine—Sinusitis—Epirubicin—liver cancer	0.000952	0.00127	CcSEcCtD
Tiagabine—Hyperglycaemia—Doxorubicin—liver cancer	0.00095	0.00127	CcSEcCtD
Tiagabine—Pneumonia—Doxorubicin—liver cancer	0.000944	0.00126	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—UGDH—liver cancer	0.000943	0.00376	CbGpPWpGaD
Tiagabine—Renal failure—Doxorubicin—liver cancer	0.000923	0.00123	CcSEcCtD
Tiagabine—Neuropathy peripheral—Doxorubicin—liver cancer	0.00092	0.00123	CcSEcCtD
Tiagabine—Haemoglobin—Epirubicin—liver cancer	0.000915	0.00122	CcSEcCtD
Tiagabine—Stomatitis—Doxorubicin—liver cancer	0.000915	0.00122	CcSEcCtD
Tiagabine—Rhinitis—Epirubicin—liver cancer	0.000913	0.00122	CcSEcCtD
Tiagabine—Conjunctivitis—Doxorubicin—liver cancer	0.000912	0.00122	CcSEcCtD
Tiagabine—Urinary tract infection—Doxorubicin—liver cancer	0.000912	0.00122	CcSEcCtD
Tiagabine—Haemorrhage—Epirubicin—liver cancer	0.000911	0.00122	CcSEcCtD
Tiagabine—Hypoaesthesia—Epirubicin—liver cancer	0.000906	0.00121	CcSEcCtD
Tiagabine—Pharyngitis—Epirubicin—liver cancer	0.000904	0.00121	CcSEcCtD
Tiagabine—Sweating—Doxorubicin—liver cancer	0.0009	0.0012	CcSEcCtD
Tiagabine—Oedema peripheral—Epirubicin—liver cancer	0.000897	0.0012	CcSEcCtD
Tiagabine—Haematuria—Doxorubicin—liver cancer	0.000895	0.00119	CcSEcCtD
Tiagabine—Epistaxis—Doxorubicin—liver cancer	0.000885	0.00118	CcSEcCtD
Tiagabine—Sinusitis—Doxorubicin—liver cancer	0.000881	0.00118	CcSEcCtD
Tiagabine—Visual impairment—Epirubicin—liver cancer	0.000878	0.00117	CcSEcCtD
Tiagabine—CYP3A4—Tryptophan metabolism—CYP2E1—liver cancer	0.000862	0.00344	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—PPARA—liver cancer	0.000861	0.00343	CbGpPWpGaD
Tiagabine—Tinnitus—Epirubicin—liver cancer	0.000849	0.00113	CcSEcCtD
Tiagabine—Haemoglobin—Doxorubicin—liver cancer	0.000847	0.00113	CcSEcCtD
Tiagabine—Rhinitis—Doxorubicin—liver cancer	0.000845	0.00113	CcSEcCtD
Tiagabine—Haemorrhage—Doxorubicin—liver cancer	0.000843	0.00112	CcSEcCtD
Tiagabine—Hypoaesthesia—Doxorubicin—liver cancer	0.000838	0.00112	CcSEcCtD
Tiagabine—Pharyngitis—Doxorubicin—liver cancer	0.000836	0.00112	CcSEcCtD
Tiagabine—Oedema peripheral—Doxorubicin—liver cancer	0.00083	0.00111	CcSEcCtD
Tiagabine—Chills—Epirubicin—liver cancer	0.000817	0.00109	CcSEcCtD
Tiagabine—Visual impairment—Doxorubicin—liver cancer	0.000812	0.00108	CcSEcCtD
Tiagabine—Alopecia—Epirubicin—liver cancer	0.000805	0.00107	CcSEcCtD
Tiagabine—Tinnitus—Doxorubicin—liver cancer	0.000786	0.00105	CcSEcCtD
Tiagabine—Flatulence—Epirubicin—liver cancer	0.000781	0.00104	CcSEcCtD
Tiagabine—Tension—Epirubicin—liver cancer	0.000778	0.00104	CcSEcCtD
Tiagabine—Dysgeusia—Epirubicin—liver cancer	0.000776	0.00104	CcSEcCtD
Tiagabine—SLC6A1—Transmission across Chemical Synapses—HRAS—liver cancer	0.000773	0.00309	CbGpPWpGaD
Tiagabine—Nervousness—Epirubicin—liver cancer	0.00077	0.00103	CcSEcCtD
Tiagabine—Back pain—Epirubicin—liver cancer	0.000767	0.00102	CcSEcCtD
Tiagabine—Muscle spasms—Epirubicin—liver cancer	0.000762	0.00102	CcSEcCtD
Tiagabine—Chills—Doxorubicin—liver cancer	0.000756	0.00101	CcSEcCtD
Tiagabine—Alopecia—Doxorubicin—liver cancer	0.000745	0.000994	CcSEcCtD
Tiagabine—Ill-defined disorder—Epirubicin—liver cancer	0.000736	0.000982	CcSEcCtD
Tiagabine—Anaemia—Epirubicin—liver cancer	0.000733	0.000978	CcSEcCtD
Tiagabine—Agitation—Epirubicin—liver cancer	0.000729	0.000972	CcSEcCtD
Tiagabine—Flatulence—Doxorubicin—liver cancer	0.000723	0.000965	CcSEcCtD
Tiagabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.000721	0.00288	CbGpPWpGaD
Tiagabine—Tension—Doxorubicin—liver cancer	0.00072	0.000961	CcSEcCtD
Tiagabine—Dysgeusia—Doxorubicin—liver cancer	0.000718	0.000959	CcSEcCtD
Tiagabine—Malaise—Epirubicin—liver cancer	0.000715	0.000954	CcSEcCtD
Tiagabine—Nervousness—Doxorubicin—liver cancer	0.000712	0.000951	CcSEcCtD
Tiagabine—Vertigo—Epirubicin—liver cancer	0.000712	0.00095	CcSEcCtD
Tiagabine—Syncope—Epirubicin—liver cancer	0.000711	0.000949	CcSEcCtD
Tiagabine—Leukopenia—Epirubicin—liver cancer	0.00071	0.000947	CcSEcCtD
Tiagabine—Back pain—Doxorubicin—liver cancer	0.00071	0.000947	CcSEcCtD
Tiagabine—Muscle spasms—Doxorubicin—liver cancer	0.000705	0.000941	CcSEcCtD
Tiagabine—Palpitations—Epirubicin—liver cancer	0.000701	0.000935	CcSEcCtD
Tiagabine—Loss of consciousness—Epirubicin—liver cancer	0.000697	0.00093	CcSEcCtD
Tiagabine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.000697	0.00278	CbGpPWpGaD
Tiagabine—Cough—Epirubicin—liver cancer	0.000692	0.000923	CcSEcCtD
Tiagabine—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.000687	0.00274	CbGpPWpGaD
Tiagabine—Hypertension—Epirubicin—liver cancer	0.000684	0.000913	CcSEcCtD
Tiagabine—Ill-defined disorder—Doxorubicin—liver cancer	0.000681	0.000908	CcSEcCtD
Tiagabine—Anaemia—Doxorubicin—liver cancer	0.000678	0.000905	CcSEcCtD
Tiagabine—Chest pain—Epirubicin—liver cancer	0.000675	0.000901	CcSEcCtD
Tiagabine—Myalgia—Epirubicin—liver cancer	0.000675	0.000901	CcSEcCtD
Tiagabine—Arthralgia—Epirubicin—liver cancer	0.000675	0.000901	CcSEcCtD
Tiagabine—Agitation—Doxorubicin—liver cancer	0.000674	0.0009	CcSEcCtD
Tiagabine—Anxiety—Epirubicin—liver cancer	0.000673	0.000898	CcSEcCtD
Tiagabine—Discomfort—Epirubicin—liver cancer	0.000667	0.00089	CcSEcCtD
Tiagabine—Malaise—Doxorubicin—liver cancer	0.000661	0.000883	CcSEcCtD
Tiagabine—Dry mouth—Epirubicin—liver cancer	0.00066	0.000881	CcSEcCtD
Tiagabine—Vertigo—Doxorubicin—liver cancer	0.000659	0.000879	CcSEcCtD
Tiagabine—Syncope—Doxorubicin—liver cancer	0.000658	0.000878	CcSEcCtD
Tiagabine—Leukopenia—Doxorubicin—liver cancer	0.000657	0.000876	CcSEcCtD
Tiagabine—Confusional state—Epirubicin—liver cancer	0.000652	0.000871	CcSEcCtD
Tiagabine—Palpitations—Doxorubicin—liver cancer	0.000648	0.000865	CcSEcCtD
Tiagabine—Oedema—Epirubicin—liver cancer	0.000647	0.000863	CcSEcCtD
Tiagabine—Loss of consciousness—Doxorubicin—liver cancer	0.000645	0.00086	CcSEcCtD
Tiagabine—Infection—Epirubicin—liver cancer	0.000643	0.000858	CcSEcCtD
Tiagabine—Cough—Doxorubicin—liver cancer	0.00064	0.000854	CcSEcCtD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—ALB—liver cancer	0.00064	0.00255	CbGpPWpGaD
Tiagabine—Shock—Epirubicin—liver cancer	0.000637	0.000849	CcSEcCtD
Tiagabine—Thrombocytopenia—Epirubicin—liver cancer	0.000633	0.000845	CcSEcCtD
Tiagabine—Hypertension—Doxorubicin—liver cancer	0.000633	0.000845	CcSEcCtD
Tiagabine—Tachycardia—Epirubicin—liver cancer	0.000631	0.000843	CcSEcCtD
Tiagabine—Hyperhidrosis—Epirubicin—liver cancer	0.000625	0.000835	CcSEcCtD
Tiagabine—Arthralgia—Doxorubicin—liver cancer	0.000624	0.000833	CcSEcCtD
Tiagabine—Chest pain—Doxorubicin—liver cancer	0.000624	0.000833	CcSEcCtD
Tiagabine—Myalgia—Doxorubicin—liver cancer	0.000624	0.000833	CcSEcCtD
Tiagabine—Anxiety—Doxorubicin—liver cancer	0.000622	0.00083	CcSEcCtD
Tiagabine—CYP3A4—Tryptophan metabolism—CYP1A1—liver cancer	0.000619	0.00247	CbGpPWpGaD
Tiagabine—Discomfort—Doxorubicin—liver cancer	0.000617	0.000823	CcSEcCtD
Tiagabine—Anorexia—Epirubicin—liver cancer	0.000617	0.000823	CcSEcCtD
Tiagabine—Dry mouth—Doxorubicin—liver cancer	0.000611	0.000815	CcSEcCtD
Tiagabine—Hypotension—Epirubicin—liver cancer	0.000605	0.000807	CcSEcCtD
Tiagabine—Confusional state—Doxorubicin—liver cancer	0.000604	0.000806	CcSEcCtD
Tiagabine—Oedema—Doxorubicin—liver cancer	0.000599	0.000799	CcSEcCtD
Tiagabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000596	0.00238	CbGpPWpGaD
Tiagabine—Infection—Doxorubicin—liver cancer	0.000595	0.000794	CcSEcCtD
Tiagabine—SLC6A1—Neuronal System—HRAS—liver cancer	0.000592	0.00236	CbGpPWpGaD
Tiagabine—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000589	0.000787	CcSEcCtD
Tiagabine—Shock—Doxorubicin—liver cancer	0.000589	0.000786	CcSEcCtD
Tiagabine—Thrombocytopenia—Doxorubicin—liver cancer	0.000586	0.000782	CcSEcCtD
Tiagabine—Insomnia—Epirubicin—liver cancer	0.000585	0.000781	CcSEcCtD
Tiagabine—Tachycardia—Doxorubicin—liver cancer	0.000584	0.00078	CcSEcCtD
Tiagabine—Paraesthesia—Epirubicin—liver cancer	0.000581	0.000775	CcSEcCtD
Tiagabine—Hyperhidrosis—Doxorubicin—liver cancer	0.000579	0.000772	CcSEcCtD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—RAF1—liver cancer	0.000578	0.00231	CbGpPWpGaD
Tiagabine—Dyspnoea—Epirubicin—liver cancer	0.000577	0.00077	CcSEcCtD
Tiagabine—Somnolence—Epirubicin—liver cancer	0.000575	0.000768	CcSEcCtD
Tiagabine—Anorexia—Doxorubicin—liver cancer	0.000571	0.000762	CcSEcCtD
Tiagabine—Dyspepsia—Epirubicin—liver cancer	0.00057	0.00076	CcSEcCtD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000565	0.00225	CbGpPWpGaD
Tiagabine—Decreased appetite—Epirubicin—liver cancer	0.000562	0.000751	CcSEcCtD
Tiagabine—Hypotension—Doxorubicin—liver cancer	0.000559	0.000746	CcSEcCtD
Tiagabine—Fatigue—Epirubicin—liver cancer	0.000558	0.000744	CcSEcCtD
Tiagabine—Constipation—Epirubicin—liver cancer	0.000553	0.000738	CcSEcCtD
Tiagabine—Pain—Epirubicin—liver cancer	0.000553	0.000738	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—NR1H4—liver cancer	0.000551	0.0022	CbGpPWpGaD
Tiagabine—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000545	0.000728	CcSEcCtD
Tiagabine—Insomnia—Doxorubicin—liver cancer	0.000541	0.000723	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—GSTA3—liver cancer	0.000541	0.00216	CbGpPWpGaD
Tiagabine—Paraesthesia—Doxorubicin—liver cancer	0.000538	0.000717	CcSEcCtD
Tiagabine—CYP3A4—Metapathway biotransformation—GSTA3—liver cancer	0.000534	0.00213	CbGpPWpGaD
Tiagabine—Dyspnoea—Doxorubicin—liver cancer	0.000534	0.000712	CcSEcCtD
Tiagabine—Feeling abnormal—Epirubicin—liver cancer	0.000533	0.000711	CcSEcCtD
Tiagabine—Somnolence—Doxorubicin—liver cancer	0.000532	0.00071	CcSEcCtD
Tiagabine—Gastrointestinal pain—Epirubicin—liver cancer	0.000529	0.000706	CcSEcCtD
Tiagabine—Dyspepsia—Doxorubicin—liver cancer	0.000527	0.000703	CcSEcCtD
Tiagabine—Decreased appetite—Doxorubicin—liver cancer	0.00052	0.000694	CcSEcCtD
Tiagabine—Fatigue—Doxorubicin—liver cancer	0.000516	0.000689	CcSEcCtD
Tiagabine—Urticaria—Epirubicin—liver cancer	0.000514	0.000686	CcSEcCtD
Tiagabine—Pain—Doxorubicin—liver cancer	0.000512	0.000683	CcSEcCtD
Tiagabine—Constipation—Doxorubicin—liver cancer	0.000512	0.000683	CcSEcCtD
Tiagabine—Body temperature increased—Epirubicin—liver cancer	0.000511	0.000683	CcSEcCtD
Tiagabine—Abdominal pain—Epirubicin—liver cancer	0.000511	0.000683	CcSEcCtD
Tiagabine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.0005	0.002	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—GSTA4—liver cancer	0.000495	0.00198	CbGpPWpGaD
Tiagabine—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000494	0.00197	CbGpPWpGaD
Tiagabine—Feeling abnormal—Doxorubicin—liver cancer	0.000493	0.000658	CcSEcCtD
Tiagabine—Gastrointestinal pain—Doxorubicin—liver cancer	0.00049	0.000653	CcSEcCtD
Tiagabine—CYP3A4—Metapathway biotransformation—GSTA4—liver cancer	0.000488	0.00195	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—GSTA2—liver cancer	0.000483	0.00193	CbGpPWpGaD
Tiagabine—Hypersensitivity—Epirubicin—liver cancer	0.000477	0.000636	CcSEcCtD
Tiagabine—Urticaria—Doxorubicin—liver cancer	0.000476	0.000635	CcSEcCtD
Tiagabine—Abdominal pain—Doxorubicin—liver cancer	0.000473	0.000632	CcSEcCtD
Tiagabine—Body temperature increased—Doxorubicin—liver cancer	0.000473	0.000632	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—GSTA1—liver cancer	0.000466	0.00186	CbGpPWpGaD
Tiagabine—Asthenia—Epirubicin—liver cancer	0.000464	0.000619	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—NAT2—liver cancer	0.00046	0.00184	CbGpPWpGaD
Tiagabine—Pruritus—Epirubicin—liver cancer	0.000458	0.000611	CcSEcCtD
Tiagabine—CYP3A4—Metapathway biotransformation—NAT2—liver cancer	0.000454	0.00181	CbGpPWpGaD
Tiagabine—Diarrhoea—Epirubicin—liver cancer	0.000443	0.000591	CcSEcCtD
Tiagabine—Hypersensitivity—Doxorubicin—liver cancer	0.000441	0.000589	CcSEcCtD
Tiagabine—Asthenia—Doxorubicin—liver cancer	0.00043	0.000573	CcSEcCtD
Tiagabine—Dizziness—Epirubicin—liver cancer	0.000428	0.000571	CcSEcCtD
Tiagabine—Pruritus—Doxorubicin—liver cancer	0.000424	0.000565	CcSEcCtD
Tiagabine—Vomiting—Epirubicin—liver cancer	0.000411	0.000549	CcSEcCtD
Tiagabine—Diarrhoea—Doxorubicin—liver cancer	0.00041	0.000547	CcSEcCtD
Tiagabine—Rash—Epirubicin—liver cancer	0.000408	0.000544	CcSEcCtD
Tiagabine—Dermatitis—Epirubicin—liver cancer	0.000408	0.000544	CcSEcCtD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000406	0.00162	CbGpPWpGaD
Tiagabine—Headache—Epirubicin—liver cancer	0.000405	0.000541	CcSEcCtD
Tiagabine—Dizziness—Doxorubicin—liver cancer	0.000396	0.000528	CcSEcCtD
Tiagabine—CYP3A4—Metapathway biotransformation—GPX3—liver cancer	0.000386	0.00154	CbGpPWpGaD
Tiagabine—Nausea—Epirubicin—liver cancer	0.000384	0.000513	CcSEcCtD
Tiagabine—Vomiting—Doxorubicin—liver cancer	0.000381	0.000508	CcSEcCtD
Tiagabine—Rash—Doxorubicin—liver cancer	0.000377	0.000504	CcSEcCtD
Tiagabine—Dermatitis—Doxorubicin—liver cancer	0.000377	0.000503	CcSEcCtD
Tiagabine—Headache—Doxorubicin—liver cancer	0.000375	0.0005	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—HPGDS—liver cancer	0.000368	0.00147	CbGpPWpGaD
Tiagabine—Nausea—Doxorubicin—liver cancer	0.000356	0.000475	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—CYP2E1—liver cancer	0.0003	0.0012	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—CYP2E1—liver cancer	0.000296	0.00118	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—GGT1—liver cancer	0.000275	0.0011	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—GSTP1—liver cancer	0.000247	0.000987	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	0.000244	0.000973	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—GSTM1—liver cancer	0.000227	0.000907	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	0.000224	0.000895	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—CYP1A1—liver cancer	0.000216	0.00086	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	0.000213	0.000848	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—UGDH—liver cancer	0.000161	0.000643	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—EPT1—liver cancer	0.000152	0.000605	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—TAT—liver cancer	0.000144	0.000573	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CPT1B—liver cancer	9.77e-05	0.00039	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GLUL—liver cancer	9.77e-05	0.00039	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—NR1H4—liver cancer	9.42e-05	0.000376	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GSTA3—liver cancer	9.26e-05	0.000369	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GSTA4—liver cancer	8.47e-05	0.000338	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GSTA2—liver cancer	8.25e-05	0.000329	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GSTA1—liver cancer	7.96e-05	0.000318	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—NAT2—liver cancer	7.87e-05	0.000314	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—ALDOB—liver cancer	7.55e-05	0.000301	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CRABP1—liver cancer	7.2e-05	0.000287	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—HPGDS—liver cancer	6.29e-05	0.000251	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PSMA4—liver cancer	5.61e-05	0.000224	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PSMD10—liver cancer	5.61e-05	0.000224	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GOT2—liver cancer	5.46e-05	0.000218	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CYP2E1—liver cancer	5.13e-05	0.000205	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CYCS—liver cancer	4.8e-05	0.000192	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GOT1—liver cancer	4.71e-05	0.000188	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GGT1—liver cancer	4.71e-05	0.000188	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GSTP1—liver cancer	4.23e-05	0.000169	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—HMOX1—liver cancer	4.17e-05	0.000166	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GSTM1—liver cancer	3.89e-05	0.000155	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CYP1A1—liver cancer	3.69e-05	0.000147	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—MTHFR—liver cancer	3.44e-05	0.000137	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PPARA—liver cancer	3.37e-05	0.000134	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PIK3CG—liver cancer	2.89e-05	0.000115	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PPARG—liver cancer	2.79e-05	0.000111	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PIK3CD—liver cancer	2.54e-05	0.000101	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—ALB—liver cancer	2.51e-05	0.0001	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PIK3CB—liver cancer	2.21e-05	8.83e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PIK3CA—liver cancer	1.35e-05	5.38e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—AKT1—liver cancer	1.1e-05	4.4e-05	CbGpPWpGaD
